Cargando…

Interleukin-17: A potential therapeutic target in COVID-19

Detalles Bibliográficos
Autor principal:	Mendoza, Vicky M. Montaño
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834707/ https://www.ncbi.nlm.nih.gov/pubmed/32504739 http://dx.doi.org/10.1016/j.jinf.2020.05.072

Ejemplares similares

REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19
por: Piaserico, Stefano, et al.
Publicado: (2020)

Targeting N17 domain as a potential therapeutic target for the treatment of Huntington disease: An opinion
por: Kumar, Vishal, et al.
Publicado: (2021)

Interleukin-6 as a potential biomarker of COVID-19 progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020)

Severe Acute Respiratory Syndrome–Coronavirus-2 Infection and Patients With Lung Cancer: The Potential Role of Interleukin-17 Target Therapy
por: Cafarotti, Stefano
Publicado: (2020)

Candidiasis in patients treated with interleukin-17 inhibitors
por: Báez-Gutierrez, Nerea, et al.
Publicado: (2021)

Pharmacological targeting of HMGB-1 translocation: A potential therapeutic strategy for COVID-19
por: Bagheri, Vahid
Publicado: (2022)

Interleukin-17 as a potential therapeutic target for chronic pain
por: Jiang, Xiaojuan, et al.
Publicado: (2022)

Role of the interleukin-17 pathway in the pathogenesis of atrial fibrillation associated with inflammation
por: Yue, Honghua, et al.
Publicado: (2021)

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
por: Vityala, Yethindra, et al.
Publicado: (2021)

Clofazimine: A potential therapeutic option for severe COVID-19
por: Ateya, Areej Mohamed
Publicado: (2021)

Potential Therapeutic Effects of Virgin Coconut Oil on COVID-19
por: Ghorbannezhad, Ghazaleh, et al.
Publicado: (2022)

Interleukin-6 and severity of COVID-19 patients in Hefei, China
por: Zhao, Z., et al.
Publicado: (2020)

Complement activation in patients with COVID-19: A novel therapeutic target
por: Cugno, Massimo, et al.
Publicado: (2020)

A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19
por: Esam, Zohreh
Publicado: (2020)

Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid
por: Unal, Gokhan, et al.
Publicado: (2020)

Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
por: Kapur, Ajita, et al.
Publicado: (2022)

COVID-19 in CVID: a Case Series of 17 Patients
por: Greenmyer, Jacob R., et al.
Publicado: (2021)

Cyr61: a potential therapeutic target for prostate cancer
por: Lin, Chang-Ming, et al.
Publicado: (2014)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

Therapeutic potential for clomiphene, a selective estrogen receptor modulator, in the treatment of COVID‐19
por: Ghasemnejad-Berenji, Morteza, et al.
Publicado: (2020)

Interleukin-17: Potential Target for Chronic Wounds
por: Hadian, Yasmin, et al.
Publicado: (2019)

Off‐target ACE2 ligands: Possible therapeutic option for CoVid‐19?
por: Brogi, Simone, et al.
Publicado: (2020)

Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19
por: Gade, Akhil R., et al.
Publicado: (2020)

Romeo and Juliet: Revisited (at the time of COVID-19)
por: Costantino, Giorgio, et al.
Publicado: (2020)

Databases for the targeted COVID‐19 therapeutics
por: Wang, Yunxia, et al.
Publicado: (2020)

COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications
por: Barchetta, Ilaria, et al.
Publicado: (2020)

Interleukin-6 and statin therapy: potential role in the management of COPD
por: Young, Robert P, et al.
Publicado: (2013)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

Kinetics of serum hepcidin and interleukin-6 levels following COVID-19 infection in hemodialysis patients
por: Touzot, Maxime, et al.
Publicado: (2021)

Genetic variation of interleukin-1 receptor type 1 is associated with severity of COVID-19 disease
por: Wang, Renxi
Publicado: (2022)

Proteomics profiling of colorectal cancer progression identifies PLOD2 as a potential therapeutic target
por: Shao, Yingkuan, et al.
Publicado: (2021)

COVID-19: Ophthalmic prophylactic and therapeutic measures
por: Waikar, Shrikant, et al.
Publicado: (2020)

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

COVID-19: Brief overview of therapeutic strategies
por: Beaumont, Anne-Lise, et al.
Publicado: (2023)

HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
por: Khan, A N, et al.
Publicado: (2006)

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
por: Takamura, Saori, et al.
Publicado: (2022)

Low serum CCL17 as a marker for severe/critical COVID-19: A pathogenic link
por: Sharma, Abhay
Publicado: (2021)

Identification of potential vaccine targets for COVID‐19 by combining single‐cell and bulk TCR sequencing
por: Wang, Pingping, et al.
Publicado: (2021)

The chemokine CCL17 is a novel therapeutic target for cardiovascular aging
por: Zhang, Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cjuf025rk5khd1mf8tq07qnjtk